Learn about integrative obesity and cardiometabolic care, an innovative approach to better manage weight and metabolic health.

Abstract: Navigating Health in Your 40s, 50s, and Beyond

Welcome to this comprehensive educational post. I am Dr. Alex Jimenez, and I will walk you through a clear, evidence-based journey to understand health optimization in adults aged 40 to 60. This is a pivotal stage of life where the long-term effects of lifestyle and metabolic change begin to emerge, especially for individuals living with obesity or sarcopenic obesity. In an easy-to-read, first-person narrative, I will explain the physiology and latest clinical research on cardiometabolic health, liver function, sleep quality, mental health, sarcopenia, musculoskeletal pain, menopause, and how modern obesity therapeutics reshape outcomes. You will learn why treating obesity is foundational to reducing cardiovascular risk, how targeted weight loss improves hypertension, dyslipidemia, and insulin resistance, and how to integrate chiropractic care, rehabilitation, therapeutic nutrition, and pharmacotherapy safely and effectively.

At Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, I work in a multidisciplinary, integrative care model with Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933). Dr. Cardenas serves as our Medical Director and Collaborative Physician and brings over 40 years of internal medicine leadership to ensure medical oversight, cardiovascular risk management, medication safety, and coordinated care. Together, our team integrates chiropractic care (my role), functional medicine, personal injury care, rehabilitation, nutrition, sleep medicine coordination, and advanced metabolic therapeutics (such as GLP-1 and dual-agonist therapies) to treat the whole person.

This post will:

• Explain why our treatment goals emphasize reducing adiposity, preserving lean muscle, and optimizing quality of life.
• Translate modern trials like SELECT, STEP-HFpEF, and SUMMIT into practical protocols that reduce major adverse cardiovascular events and improve heart failure symptoms.
• Detail the bidirectional links among obesity, insulin resistance, hypertension, dyslipidemia, sleep apnea, and liver disease.
• Show precisely how integrative chiropractic care fits and accelerates outcomes by reducing pain, improving biomechanics, modulating autonomic function, and enabling consistent physical activity.
• Provide clinical case journeys that demonstrate stepwise decision-making and patient-centered progress.
• Give you step-by-step guidance for nutrition, exercise, sleep, stress, and medication optimization—with clear rationales and safety considerations.
• Include APA-7-style citations with hyperlinked references and incorporate clinical observations from my practice documented at Chiropracticscientist.com and my professional timeline on LinkedIn.

By reading this post, you will gain a working understanding of why small, sustained changes in weight, sleep, nutrition, and activity can produce meaningful improvements in health—often with visible results within months. You will also see how a well-coordinated team that integrates chiropractic care with internal medicine oversight can translate modern research into real-world outcomes.

Our Integrative Practice: Medical Direction, Chiropractic Integration, Functional Medicine, Rehabilitation, and Personal Injury Care

I introduce our collaborative framework because comprehensive outcomes require coordinated expertise and clear medical leadership.

• Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933):

• Medical Director and Collaborative Physician at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic).
• Over 40 years of experience in internal medicine guiding diagnostics, cardiometabolic risk management, medication protocols, sleep medicine coordination, and safety across multidisciplinary treatments.
• Oversees pharmacotherapy choices, contraindication screening, lab and imaging interpretation, and guideline alignment for hypertension, dyslipidemia, diabetes, and obesity treatment.

• Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST:

• I serve as a chiropractic physician and advanced practice registered nurse focusing on integrative chiropractic care, functional medicine, rehabilitation, metabolic optimization, pain science, autonomic regulation, and movement restoration.
• I integrate manual therapy, adjustments, neuromuscular re-education, biomechanical optimization, postural and breathing mechanics coaching, and graded rehabilitation to enable patients to engage in therapeutic physical activity that improves cardiometabolic health.
• I document clinical observations and translational insights at Chiropracticscientist.com and my professional timeline on LinkedIn.

• Multidisciplinary team roles:

• Physical therapists and rehabilitation specialists coordinate progressive exercise, neuromuscular re-education, balance and gait optimization, and kinetic chain correction.
• Nutrition professionals structure therapeutic diets (DASH, Mediterranean, low-carbohydrate, protein-forward, fiber-optimized) tailored to metabolic goals and individual lifestyles.
• Behavioral health collaborators support adherence, stress resilience, sleep hygiene, and cognitive-behavioral strategies for pain and weight management.
• Case management and personal injury coordinators ensure continuity for patients in workers’ compensation or motor vehicle injury contexts, integrating objective outcomes and necessary reporting.

How we integrate chiropractic care with medical oversight:

• Medical direction:

• Cardenas anchors diagnostics, medication decisions, safety protocols, advanced lipid and glucose testing, sleep and cardiology referrals, and specialist coordination.

• Chiropractic integration:

• My care addresses biomechanical contributors to pain and movement inefficiency, thoracic cage dynamics, breathing mechanics relevant to sleep apnea, and autonomic modulation.
• Techniques include high-velocity low-amplitude (HVLA) adjustments when indicated, low-force mobilization, myofascial release, neuromuscular activation, proprioceptive training, postural strategies, and graded rehabilitation.
• The goal: reduce pain, restore function, enable consistent physical activity, and support cardiometabolic improvements through sustained movement.

• Functional medicine overlay:

• Root-cause frameworks targeting insulin resistance, inflammation, sleep dysregulation, and hormonal transitions.
• Personalized nutrition and lifestyle protocols with phased implementation across diet, physical activity, sleep, and stress.

• Personal injury care:

• For injured patients, protocols focus on pain control, soft-tissue healing, range-of-motion restoration, and return to duty while maintaining metabolic treatments that reduce cardiometabolic risk.

• Rehabilitation synergy:

• Stepwise progression plans matched to metabolic therapies (e.g., semaglutide or tirzepatide) to scale capacity, preserve lean mass, and safely increase workload.

Redefining Obesity Treatment Goals: Why We Aim Beyond the Scale

Before we dive into specific conditions common in ages 40 to 60, let’s define the foundation for our therapeutic approach to obesity.

Our primary objectives are multifaceted and patient-centered:

• Reduce adiposity, not just weight:

• We prioritize decreasing metabolically harmful visceral fat. Indiscriminate weight loss with significant muscle loss compromises basal metabolic rate and long-term health.

• Prevent and mitigate obesity-related complications:

• Obesity is a chronic disease that opens the door to type 2 diabetes, cardiovascular disease, certain cancers, sleep apnea, fatty liver disease, and osteoarthritis. We aim to halt progression and reverse where possible.

• Preserve lean muscle mass and function:

• Muscle is metabolically active and foundational for strength, mobility, insulin sensitivity, and cardiometabolic resilience. We implement targeted protein and resistance strategies to protect and enhance muscle—critical for combating sarcopenia as we age.

• Improve quality of life:

• Better energy, reduced pain, improved sleep, enhanced mood, and meaningful engagement with daily activities. Small early wins often yield immediate improvements in day-to-day well-being and motivation.

Why incremental progress matters:

• Even modest weight reduction produces measurable health benefits across prediabetes, type 2 diabetes, dyslipidemia, hypertension, fatty liver disease, osteoarthritis, mobility, depression, and overall quality of life (Ryan & Yockey, 2017).
• We celebrate 2.5%, 5%, 10%, and 15% milestones because physiology responds in tiers:

• Prediabetes and type 2 diabetes often improve starting at 2.5%, with remission potential at larger losses (Lingvay et al., 2022).
• Dyslipidemia: significant improvements commonly start around 5% and continue through 15%.
• Hypertension: clinically meaningful reductions often emerge around 10%.
• MASLD: reversal of hepatic steatosis usually requires 10% or more (Donnelly et al., 2005).
• Osteoarthritis: every pound lost reduces knee joint load by approximately four pounds; benefits often begin around 5%.
• Quality of life and mood: common improvements around 5%, frequently observed earlier in practice.
• Mobility: meaningful gains around 5% and compounded with resistance training.

These thresholds empower realistic goal-setting and celebrate each achievement.

References:

• Weight Loss and Improvement in Comorbidities: Differences at 5%, 10%, 15%, and Over (Ryan & Yockey, 2017)
• Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation (Lingvay et al., 2022)
• Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease (Donnelly et al., 2005)

Cardiometabolic Health: The Core Physiology of Obesity and Insulin Resistance

Cardiometabolic health is the foundation upon which many midlife complications sit. Understanding this physiology clarifies why integrative, multi-domain interventions are effective.

The bidirectional relationship:

• Obesity and cardiometabolic syndrome exacerbate one another through inflammation, insulin resistance, dyslipidemia, hypertension, and endothelial dysfunction.
• Visceral adipose tissue functions as an endocrine organ that secretes inflammatory cytokines (e.g., TNF-?, IL-6) and adipokines, driving a chronic, low-grade pro-inflammatory state that impairs insulin signaling in muscle, liver, and fat.

Physiologic cascade:

• Inflammation and insulin resistance:

• Cytokines interfere with insulin receptor signaling, reducing glucose uptake and promoting compensatory hyperinsulinemia. Elevated insulin levels drive hepatic de novo lipogenesis, elevate triglycerides, and favor fat storage.

• Hemodynamic changes and blood pressure:

• Endothelial dysfunction and sympathetic/RAAS activation increase vasoconstriction and blood volume, elevating blood pressure.

• Dyslipidemia:

• Insulin resistance dysregulates hepatic lipid handling, raises triglycerides and small dense LDL, lowers HDL, and sends free fatty acids to tissues (muscle, liver), further worsening insulin resistance.

Metabolic syndrome criteria (three of five):

• Increased abdominal waist circumference:

• Men >40 inches; women >35 inches. A direct proxy for visceral adiposity.

• Elevated triglycerides> 150 mg/dL or medication use.
• Low HDL cholesterol:

• Men <40 mg/dL; women <50 mg/dL.

• Elevated blood pressure:

• Systolic ? 130 mmHg or diastolic  ? 85 mmHg, or medication use.

• Elevated fasting glucose? 100 mg/dL or type 2 diabetes.

Comprehensive cardiovascular risk profiling in our clinic:

• Clinical measurements:

• Accurate blood pressure, waist circumference, body composition quantification (BIA, DEXA).

• Imaging:

• Coronary artery calcium (CAC) scoring to stratify risk and motivate behavior change.

• Laboratory workup:

• Fasting lipids (total, LDL, HDL, triglycerides), ApoB for atherogenic particle count, Lipoprotein(a), fasting glucose, HbA1c.

• Psychosocial evaluation:

• Screen for sleep, stress, anxiety, and depression to integrate behavioral interventions.

References:

• Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association (Powell-Wiley et al., 2021)
• Guideline on the Management of Blood Cholesterol (Grundy et al., 2019)
• 2017 ACC/AHA Guideline for High Blood Pressure in Adults (Whelton et al., 2018)

Cardiovascular Disease: Fat Mass Disease, Inflammation, and Arrhythmia Risk

Excess adiposity harms the heart through direct mechanical effects and indirect metabolic/hormonal effects.

Direct mechanical effects (fat mass disease):

• Pericardial fat (outside the pericardium) and epicardial fat (beneath the pericardium) stiffen the heart and bathe coronary arteries in pro-inflammatory cytokines.
• Epicardial fat shares blood supply with myocardium; its inflammatory milieu accelerates atherosclerotic plaque (ASCVD), impairs diastolic relaxation, and increases risk for HFpEF (heart failure with preserved ejection fraction).

Indirect metabolic and neurohormonal effects:

• Systemic inflammation fuels plaque formation and endothelial dysfunction.
• Increased blood volume and cardiac output trigger remodeling (e.g., left ventricular hypertrophy).
• Obesity drives co-risk factors: hypertension, sleep apnea, insulin resistance, type 2 diabetes.
• Sympathetic and RAAS activation elevate blood pressure and cardiac workload.
• Arrhythmias:

• Inflammation and fat infiltration disrupt conduction pathways, increasing the risk of atrial fibrillation.

References:

• The incredible expanding waistline: the emerging role of visceral and epicardial fat in heart failure with preserved ejection fraction (Borlaug & Jensen, 2013)
• The “skinny” on visceral fat and its link to cardiovascular disease (Lin & Li, 2021)

Treating Obesity to Protect the Heart: Lessons from the SELECT Trial

A paradigm shift in cardiology:

• Historically, clinicians prioritized treating downstream consequences (blood pressure, lipids, glucose). SELECT demonstrates that treating obesity itself reduces major adverse cardiovascular events (MACE).

SELECT trial highlights:

• Population:

• Over 17,600 adults aged> 45 with BMI> 27 and established cardiovascular disease (prior MI, stroke, PAD), but no diabetes.

• Intervention:

• Weekly semaglutide 2.4 mg vs. placebo, on top of standard CV care.

• Outcome:

• 20% relative risk reduction in MACE (CV death, nonfatal MI, nonfatal stroke) over ~40 months.

• Implications:

• Treating obesity directly reduces cardiovascular events at a magnitude comparable to high-intensity statin therapy.
• Benefits independent of glucose-lowering, affirming a primary strategy of weight reduction for secondary prevention.

Integrating SELECT into practice:

• For patients with ASCVD and overweight/obesity, semaglutide becomes a frontline tool to reduce event risk, supported by medical oversight for contraindications and monitoring.

References:

• SELECT primary publications and major summaries are reflected in modern evidence syntheses; see also Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (Marso et al., 2016) for cardioprotection context in diabetes.

Heart Failure Prevention and Treatment: Stage A HF and HFpEF

Stage A heart failure:

• Defined by risk factors without structural disease or symptoms:

• Obesity, hypertension, type 2 diabetes, dyslipidemia, sleep apnea.

• Prevention window:

• Aggressive risk reduction and weight loss (10%–15%) can prevent progression to symptomatic heart failure.

Our four-pillar approach for Stage A HF:

1. Integrative chiropractic and rehabilitative care:

• Reduce pain, restore joint mechanics, optimize neuromuscular function, and support adherence to graded aerobic exercise.
• Chiropractic adjustments, mobilizations, soft-tissue therapy, and neuromuscular re-education tailored to the spine, knees, hips, and thoracic cage for breathing mechanics and autonomic balance.

• Therapeutic nutrition:

• DASH or Mediterranean-style patterns: anti-inflammatory, fiber-rich, low in saturated fat and refined carbohydrates, personalized for sensitivities and gut health.

• Prescribed physical activity:

• At least 150 minutes/week of moderate-intensity exercise, progressing safely under rehab guidance; immediate endothelial benefits and long-term reductions in inflammation and blood pressure.

• Medical and behavioral support under Dr. Cardenas:

• Optimize blood pressure and glycemia; screen and treat sleep apnea; tools for stress management; consider obesity pharmacotherapy (e.g., semaglutide) to achieve 10%–15% weight loss.

New hope for HFpEF:

• STEP-HFpEF:

• Semaglutide 2.4 mg in obesity + HFpEF: ~13% weight loss; improved KCCQ symptoms and 6-minute walk distance; reduced CRP.

• SUMMIT:

• Tirzepatide in obesity + HFpEF: lower risk of CV death or worsening HF events; improved symptoms and functional status.

References:

• STEP-HFpEF and SUMMIT trials presented in leading cardiometabolic literature; see translational context in Obesity and Cardiovascular Disease: A Scientific Statement (Powell-Wiley et al., 2021)

Atherogenic Dyslipidemia: Beyond Standard Panels with ApoB and Lp(a)

Pattern in insulin resistance:

• High triglycerides, low HDL, and small dense LDL are highly atherogenic.
• Weight reduction, improved insulin sensitivity, and exercise reverse this pattern.

Clinical evaluation:

• Standard lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides).
• Advanced markers:

• ApoB counts all atherogenic particles (LDL, VLDL, IDL); superior predictor of risk over LDL-C alone.
• Lp(a) for genetic risk assessment; lifestyle interventions do not lower Lp(a), but managing overall risk weighting is critical.

• Risk tools:

• ASCVD risk calculators to determine statin intensity.

Treatment approach:

• Weight reduction target: 5%–15%.
• Nutrition:

• Mediterranean-style with soluble fiber (oats, barley, beans, apples) and minimized refined carbohydrates to lower triglycerides.

• Physical activity:

• > 150 minutes/week moderate intensity; directly improves HDL functionality and triglyceride metabolism.

• Pharmacotherapy:

• Statins under Dr. Cardenas’s oversight when indicated; combining obesity medications to lower weight and statins to lower ApoB achieves dual-lever control.

References:

• Guideline on the Management of Blood Cholesterol (Grundy et al., 2019)

Hypertension: Mechanisms and Integrated Management

Obesity’s role in hypertension:

• Responsible for ~78% of essential hypertension risk in men and ~65% in women.

Why obesity raises blood pressure:

• Kidney compression increases RAAS activation, causing vasoconstriction and sodium/water retention.
• Vascular restriction from fat mass elevates peripheral resistance.
• Increased cardiac output from greater body mass creates continuous demand.
• Inflammatory cytokines drive vasoconstriction and endothelial dysfunction.

Evidence for weight loss:

• Framingham data link 10 lb weight gain to ~4.5 mmHg rise in systolic BP.
• Meta-analyses show 3%–9% weight loss reduces systolic and diastolic BP by ~3 mmHg.

Treatment strategy:

• Weight reduction target: 10%–15% to meaningfully lower BP and de-prescribe antihypertensives when safe.
• Nutrition:

• DASH diet emphasizing potassium, magnesium, calcium, and sodium reduction.

• Physical activity:

• 150 minutes/week moderate intensity; post-exercise hypotension and vascular benefits.

• Chiropractic and rehabilitation:

• Address musculoskeletal pain and sympathetic tone; autonomic modulation may support BP stability; ensure physical capacity for cardio.

• Medical management:

• Antihypertensives per guidelines; monitor closely during weight loss to avoid hypotension from dose reductions; choose obesity medications with neutral or beneficial BP effects (GLP-1s).

References:

• 2017 ACC/AHA Guideline for High Blood Pressure in Adults (Whelton et al., 2018)
• Obesity and Cardiovascular Disease: A Scientific Statement (Powell-Wiley et al., 2021)

Insulin Resistance: Etiology and Reversal Strategies

Insulin physiology:

• Insulin facilitates glucose entry into cells (muscle, fat, liver). In resistance, cells under-respond; the pancreas increases insulin secretion (hyperinsulinemia), maintaining euglycemia at metabolic cost while promoting fat storage and hepatic lipogenesis.

Multifactorial causes:

• Excess dysfunctional adipose tissue:

• Cytokines and free fatty acids impair signaling; ectopic fat deposition in muscle/liver disrupts insulin pathways.

• Diet:

• Refined carbohydrates and ultra-processed foods cause large glycemic excursions and sustained insulin demand.

• Sedentary lifestyle:

• Exercise enables insulin-independent glucose uptake and improves insulin sensitivity.

• Poor sleep:

• Sleep deprivation induces short-term insulin resistance; chronic poor sleep worsens metabolic function (St-Onge et al., 2017).

• Chronic stress:

• Elevated cortisol antagonizes insulin and maintains hyperglycemia.

• Gut dysbiosis:

• Increased intestinal permeability (LPS translocation) drives low-grade inflammation that blunts insulin signaling.

Functional medicine framework:

• Target the root causes: reduce inflammation, improve diet quality, increase physical activity, restore sleep architecture, mitigate stress, and repair gut health.
• Integrate chiropractic for pain relief, autonomic modulation, and movement efficiency to support adherence to exercise prescriptions.

References:

• Sleep duration and quality: impact on lifestyle behaviors and cardiometabolic health (St-Onge et al., 2017)
• Obesity: Epidemiology, Pathophysiology, and Therapeutics (Lin & Li, 2021)

Integrative Care Journey 1: Co-Managing Type 2 Diabetes, Obesity, Hypertension, Dyslipidemia, Sleep Apnea, and Knee Pain

Meet “Robert” (a composite case reflecting common patterns). My goal here is to show the sequence of decisions and how chiropractic integration accelerates outcomes.

Baseline profile:

• Weight: 275 lb; class III obesity.
• A1c: 8.7%; type 2 diabetes.
• Hypertension; dyslipidemia; obstructive sleep apnea; knee pain limiting activity.
• Medications: metformin, glipizide, statin, lisinopril.

Initial priorities:

• Sleep apnea optimization:

• CPAP adherence first to reduce sympathetic surges, improve insulin sensitivity and daytime function, and enable exercise. Mask fitting, humidification, nasal patency assessment, behavior reinforcement; chiropractic thoracic mobility and rib mechanics to support breathing comfort.

• Nutrition:

• Low-carbohydrate, high-protein, high-fiber, reduced-calorie approach; minimize ultra-processed foods; prioritize protein to preserve lean mass.

• Physical activity:

• Start with low-impact exercise (cycling, aquatic exercise, walking), progress gradually, and later add resistance training to improve insulin sensitivity and metabolic rate.

• Medication optimization:

• Transition from sulfonylurea (glipizide) to tirzepatide while continuing metformin; reduce hypoglycemia risk and avoid weight gain; titrate tirzepatide dose every 4 weeks.

• Behavioral goals:

• Establish realistic expectations; celebrate 10%, then 5% increments; monthly check-ins.

Why CPAP first:

• OSA increases insulin resistance, BP variability, inflammation, and appetite dysregulation. CPAP improves glycemic control, reduces daytime sleepiness, supports exercise adherence, and lowers CV risk (Gottlieb et al., 2010; Marin et al., 2012). Chiropractic care enhances thoracic mobility and breathing mechanics.

Nutrition rationale:

• Lower carbohydrate intake reduces postprandial glycemia and insulin demand; protein supports satiety and lean mass; fiber slows absorption and modulates microbiome; minimize ultra-processed foods (Hall et al., 2019; Ludwig & Ebbeling, 2018).

Physical activity rationale:

• Low-impact cardio respects joint pain; progressive resistance training improves insulin sensitivity, resting metabolic rate, and musculoskeletal resilience (Ivy, 1997; Phillips & Winett, 2010).
• Chiropractic care aligns joints, addresses soft tissue restrictions, and corrects motor patterns to reduce pain flares.

Medication optimization:

• Reduce and discontinue glipizide to avoid hypoglycemia and weight gain; initiate tirzepatide for superior A1c and weight reduction; maintain metformin and optimize statin/lisinopril under Dr. Cardenas’s oversight (Jastreboff et al., 2022; Frias et al., 2021; Holman et al., 2008).

Sexual health and psychosocial factors:

• Diabetes, BP, and hyperglycemia impair sexual function; stigma and stress compound symptoms. Weight reduction and glycemic/BP control improve function; provide behavioral support and targeted therapy per individual needs (Johannes et al., 2000).

Chiropractic integration:

• HVLA adjustments, low-force mobilizations, myofascial release, neuromuscular re-education, posture and breathing coaching; autonomic down-regulation supports sleep and stress resilience.

Outcomes over three years:

• Weight loss: 75 lb (~27.3% reduction).
• BMI improved from class III to overweight.
• Waist circumference reduced (central adiposity).
• BP and lipids improved.
• A1c markedly improved.

Clinical observations:

• Pain management and movement coaching improve adherence.
• CPAP magnifies metabolic benefits of nutrition and exercise.
• Weight-neutral or weight-reducing medications enable engagement with rehab.
• Manual therapy combined with resistance training and protein-forward nutrition accelerates body composition improvements.

References:

• Ultra-processed diets cause excess calorie intake and weight gain: An inpatient randomized controlled trial (Hall et al., 2019)
• The carbohydrate-insulin model of obesity: Beyond “calories in, calories out” (Ludwig & Ebbeling, 2018)
• Tirzepatide once weekly for the treatment of obesity (Jastreboff et al., 2022)
• Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (Frias et al., 2021)
• 10-year follow-up of intensive glucose control in type 2 diabetes (Holman et al., 2008)
• CPAP and metabolic syndrome (Gottlieb et al., 2010)
• OSA treatment and CV outcomes (Marin et al., 2012)
• Exercise and insulin resistance (Ivy, 1997)
• Resistance training and metabolic markers (Phillips & Winett, 2010)
• Erectile dysfunction and risk factors (Johannes et al., 2000)

Women’s Health in Midlife: Menopause, Central Adiposity, Sarcopenia, Bone Health, Vasomotor Symptoms, Sleep, and Cardiometabolic Risk

Women may spend up to 40% of their lives in menopause. This transition often involves weight gain, increased visceral adiposity, and declines in lean mass, bone integrity, sleep quality, and mood, along with higher cardiometabolic risk.

Menopausal physiology and body composition shifts:

• Estrogen decline:

• Alters lipid metabolism; increases LDL and total cholesterol; modulates appetite (ghrelin elevation); worsens insulin resistance; redistributes fat from gynoid to android patterns (visceral fat) (Carr, 2003; Toth et al., 2000).

• Muscle and bone:

• Anabolic resistance to dietary protein; reduced muscle protein synthesis efficiency; increased bone resorption relative to formation (Khosla et al., 1997; Finkelstein et al., 2008).

• Activity changes:

• Declines in moderate-to-vigorous activity due to symptoms, pain, or life demands; sleep disruption and stress further dysregulate appetite and metabolism.

Vasomotor symptoms (VMS) and weight:

• Persistent VMS often precede increased waist circumference; higher BMI and abdominal adiposity correlate with severe VMS; weight reduction reduces VMS burden (Avis et al., 2014; Thurston et al., 2011).

Cardiometabolic and health risks:

• Increased rates of CVD, insulin resistance, type 2 diabetes, sarcopenia, osteoporosis, anxiety/depression, sleep problems, genitourinary syndrome, and cognitive complaints (Manson et al., 2016).

Treatment goals:

• Prevent weight gain; reduce fat mass; stabilize or increase muscle; support bone health; improve sleep and mood; reduce cardiometabolic risk; enhance quality of life.

Most effective initial strategy:

• Treat obesity first:

• Reducing visceral fat decreases inflammatory signaling, improves insulin sensitivity and blood pressure, and ameliorates lipid profiles.
• Resistance training protects lean mass and supports basal metabolic rate.

Lifestyle and pharmacotherapy integration:

• Nutrition:

• Protein prioritization to counter anabolic resistance; lower-glycemic load carbohydrates; fiber optimization; minimize ultra-processed foods.

• Physical activity:

• Resistance training as core; moderate-to-vigorous cardio as tolerated; low-impact on flares; balance, core stability, and mobility training.

• Behavioral counseling:

• Sleep hygiene, stress regulation, habit formation.

• Sleep interventions:

• Scheduling, stimulus control, mindfulness, CBT-I; treat sleep apnea when present.

• Pharmacotherapy:

• Prefer weight-neutral or weight-reducing options; consider obesity medications when criteria are met; evaluate menopausal hormone therapy (MHT) for VMS and insulin resistance support; consider non-hormonal agents when MHT is contraindicated.

Protein needs and anabolic resistance:

• Aim for evenly distributed protein across meals (25–35 g per meal), focusing on leucine-rich sources (Morton et al., 2018; Witard et al., 2016).
• Resistance training improves sensitivity to dietary protein and stimulates mTOR pathways for muscle protein synthesis.

Chiropractic integration in menopause management:

• Pain modulation and movement optimization support regular exercise, which is essential for reducing visceral fat and preventing sarcopenia.
• Thoracic and rib mechanics influence breathing comfort and sleep; gentle mobilizations and myofascial techniques improve chest wall mobility.
• Posture and gait corrections reduce strain and enable safe axial loading for bone health.
• Autonomic balance strategies (manual therapy, breathwork) reduce sympathetic dominance and improve sleep consistency.

References:

• The emergence of the metabolic syndrome with menopause (Carr, 2003)
• Body composition and insulin resistance across menopause (Toth et al., 2000)
• Estrogen and bone turnover (Khosla et al., 1997)
• Estrogen/testosterone effects on bone (Finkelstein et al., 2008)
• Protein intake and resistance training gains (Morton et al., 2018)
• Muscle protein synthesis rates: leucine, dose, and age (Witard et al., 2016)
• Duration of vasomotor symptoms (Avis et al., 2014)
• Abdominal adiposity and hot flashes (Thurston et al., 2011)
• Menopause management and chronic disease prevention (Manson et al., 2016)

Sarcopenic Obesity: The Hidden Threat and How We Treat It

Definition:

• Sarcopenic obesity combines reduced muscle mass/strength (sarcopenia) with increased body fat. BMI may hide profound body composition differences; lower muscle with higher fat greatly worsens metabolic and functional health.

Physiologic vicious cycle:

• Increased fat mass promotes muscle breakdown via cytokines (TNF-?, IL-6) and metaflammation.
• Decreased muscle mass lowers resting metabolic rate and worsens insulin resistance, favoring further fat gain.

Assessment:

• Functional tests:

• Grip strength (dynamometer), chair stand test for lower limb function.

• Body composition:

• BIA for tracking trends; DEXA for precise measurement of fat mass, lean mass, and visceral adipose tissue.

Prevalence highlights:

• Overall adults ~16%.
• Age 20–60: ~8%.
• Age >60 ~28%.
• Ethnic disparities:

• Mexican American women >60 may have prevalence exceeding 60% in some cohorts.

• Associated with:

• Prediabetes (~20%), type 2 diabetes (~35%), MASLD (~25%), post-bariatric (~22%)—reflecting muscle loss during weight cycling.

Weight cycling:

• Restrictive diets without protein prioritization or resistance training cause muscle loss during weight reduction; regain favors fat, not muscle, progressively worsening composition.

Clinical symptoms:

• Weakness, exhaustion, movement difficulty, heaviness, decreased range not solely driven by joint pain.

Three-pronged treatment:

1. Increase physical activity:

• Cardiorespiratory exercise (150–300 minutes moderate or 75–150 minutes vigorous weekly).
• Resistance training at least twice weekly to trigger muscle protein synthesis.
• Physical therapy referrals for deconditioned patients or those with OA/balance limitations.

• Improve nutrition:

• Protein targets 1.0–1.5 g/kg ideal body weight, leucine-rich sources; whey supplementation for convenience and potency; abundant fruits and vegetables for fiber and micronutrients; reduce refined carbohydrates and ultra-processed foods.

• Address underlying factors:

• Medical management of metabolic and hormonal dysfunction under Dr. Cardenas.
• Chiropractic care to reduce pain, correct biomechanics, and enable safe exercise progression.

References:

• GLIM criteria for the diagnosis of malnutrition (Cederholm et al., 2019)
• Sarcopenia: revised European consensus (Cruz-Jentoft et al., 2019)
• Sarcopenic obesity: pathophysiology and clinical implications (Donini et al., 2016)

Case Study: Maggie — Perimenopause, Prediabetes, Early Obesity, and Lifestyle Change

Patient profile:

• 53-year-old CPA; high stress, sedentary.
• Perimenopause symptoms (hot flashes, insomnia, anxiety).
• Family history: mother diagnosed with type 2 diabetes at 58.
• Medications: levothyroxine (hypothyroidism, controlled), gabapentin (for hot flashes/insomnia).
• Lifestyle: daily dog walks; nightly wine.

Three-year progression:

• Weight: 13? 155 lb (+20 lb).
• BMI: 22.5 ? 27.5 (overweight).
• Waist circ: 33? 37 in (central adiposity; >35 in high risk).
• A1c: 5.2%? 5.8% (prediabetes).
• Fasting glucose: 88- 104 mg/dL (impaired fasting glucose).
• Triglycerides: 80? 145 mg/dL (near high).
• HDL: 65? 48 mg/dL (low for women).
• LDL: 90 125 mg/dL (borderline high).
• Fasting insulin: 11.7 mIU/L (elevated; insulin resistance).

Diagnoses:

• Overweight/early obesity with abdominal adiposity.
• Prediabetes and insulin resistance.
• Dyslipidemia pattern.
• Well-controlled hypothyroidism.

Primary treatment goals:

• Reduce total and abdominal fat; reverse prediabetes and insulin resistance; improve sleep and VMS; protect lean mass.

Nutrition protocol:

• Protein target ~90–100 g/day; evenly spaced every 3–4 hours; leucine-rich sources.
• Net carbohydrate range ~50–100 g/day, primarily from vegetables/fruits; emphasize fiber.
• Minimize processed carbs and added sugar.
• Wine reduction:

• Collaborative taper or frequency strategy to improve sleep, reduce calories, and insulin demand.

Physical activity plan:

• Continue low-intensity dog walks; add 2 higher–intensity cardio sessions weekly.
• Initiate one resistance training session weekly; progress to two with proper form and load.

Medication and hormone management (under Dr. Cardenas):

• Metformin ER 500 mg with dinner, titrate based on tolerance and labs (off-label for prediabetes when no formal T2D diagnosis).
• Re-evaluate gabapentin efficacy (associated with gradual weight gain).
• Consider MHT if appropriate to reduce VMS and insulin resistance and support quality of life.
• Sleep hygiene counseling; consider CBT-I; explore alternatives to gabapentin if needed.
• Consider anti-obesity medication (GLP-1 RA) if 3–6 months of lifestyle changes and metformin do not sufficiently improve adiposity and insulin resistance.

Power of timely intervention:

• Do not normalize declines as “just aging.” Early comprehensive intervention halts progression to type 2 diabetes and CVD. Refer to or coordinate with obesity medicine expertise where needed.

References:

• Menopause and metabolic shifts (Carr, 2003)
• Body composition changes across menopause (Toth et al., 2000)

Case Study: Maria — Advanced Disease, Sarcopenic Obesity, ASCVD, Diabetes, MASLD, and Severe Knee Osteoarthritis

Patient profile:

• 59-year-old health executive; divorced; two adult children.
• Past MI 3 years ago (ASCVD).
• Type 2 diabetes (10 years), not fully controlled.
• Hypertension (controlled), dyslipidemia (on statin), MASLD (elevated enzymes).
• Severe bilateral knee OA with significant mobility limitations.
• Medications: metformin, insulin, lisinopril, amlodipine, rosuvastatin, diclofenac.

Initial evaluation:

• BMI 35.7 (Class II obesity).
• BP 128/78 (controlled).
• A1c 7.4% (above goal).
• Triglycerides 256 mg/dL (high risk).
• HDL 37 mg/dL (low).
• Elevated ALT/AST (MASLD).

DEXA body composition:

• Body fat 57.8% (extremely high).
• Lean mass low (4th percentile vs peers).
• VAT 3.4 L (dangerously high).
• Waist circ 43.5 in (severe risk).

Diagnoses:

• Class II obesity; sarcopenic obesity; uncontrolled type 2 diabetes; hypertension; dyslipidemia with severe hypertriglyceridemia; MASLD; ASCVD (post-MI); severe bilateral knee OA.

Primary treatment goals:

• Reduce weight and improve body composition (less fat, more muscle).
• Improve diabetes control, MASLD, and triglycerides.
• Increase mobility and reduce knee pain.
• Directly treat sarcopenia.

Nutrition protocol:

• Structured low-carbohydrate, protein-forward approach; fiber emphasis; minimize refined carbs and ultra-processed foods.

Referrals and advocacy:

• Physical therapy:

• Diagnoses: sarcopenia, deconditioning, knee OA; supervised plan for safe strengthening and functional restoration.

• Orthopedic surgery:

• Evaluate for injections (corticosteroid or hyaluronic acid) or total knee replacement candidacy to break the pain-inactivity cycle.

Advocacy against bias:

• Women with obesity encounter unconscious bias; ensure comprehensive evaluation and access to full treatment options. Communicate with surgical teams to support fair, thorough care.

Medication optimization (under Dr. Cardenas):

• Initiate GLP-1 RA (semaglutide):

• Eligible due to obesity + type 2 diabetes and established ASCVD; indication to reduce MACE risk.

• Taper and discontinue insulin:

• Insulin promotes fat storage and weight gain; GLP-1 improves glycemia and supports weight loss, enabling safe insulin reduction.

Physical activity plan:

• Follow PT guidance:

• Resistance training 1–2 times weekly for knee-safe strengthening.

• Daily cardio:

• Swimming/water aerobics and stationary biking to offload knees while building fitness.

This integrated plan addresses the root metabolic disorders, reduces cardiovascular event risk, and restores functional capacity—supported by chiropractic care for movement efficiency, pain control, and autonomic modulation to facilitate adherence.

References:

• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (Marso et al., 2016)
• STEP-HFpEF, SUMMIT, and modern obesity therapeutics literature contextualized within cardiometabolic guidelines.

The Essential Nutrition Blueprint: Protein Prioritization, Leucine, Whey, Fiber, and Whole Foods

Why protein matters in midlife:

• Anabolic resistance reduces muscle protein synthesis response to dietary protein; higher protein doses and resistance training are required to trigger robust MPS.
• Protein supports satiety and reduces total energy intake; it protects lean mass during weight loss, which is critical for preventing sarcopenic obesity.

Key strategies:

• Animal protein superiority:

• Complete amino acid profiles with higher leucine concentrations (e.g., dairy, eggs, lean meat, fish) stimulate MPS more effectively.

• Protein pacing:

• Consume significant protein every 3–4 hours; maximize the per-meal leucine threshold to “flip” the MPS switch; distribute evenly across meals (25–35 g each).

• Whey protein supplementation:

• Fast-acting; post-exercise spikes amino acids to robustly stimulate MPS; fortified whey with leucine and vitamin D supports muscle and functional strength.

• Healthy plate foundation:

• Build meals around protein; add colorful vegetables and fruits; ensure fiber for satiety, microbiome health, and stable glycemia.

• Reduce ultra-processed foods:

• Lower refined sugars and saturated processed fats; reduce energy density; decrease inflammatory burden and insulin demand.

Clinical rationale:

• Combining protein prioritization with resistance training restores MPS efficiency; preserving and building muscle improves insulin sensitivity, basal metabolic rate, and mobility.

References:

• Protein intake and resistance training-induced gains (Morton et al., 2018)
• Muscle protein synthesis: leucine, dose, and age (Witard et al., 2016)

Physical Activity: Evidence-Based Guidelines and Stepwise Implementation

Guideline targets:

• Aerobic:

• 150–300 minutes/week moderate or 75–150 minutes/week vigorous; benefits accrue beyond minimums; spread activity throughout the week.

• Muscle-strengthening:

• Resistance training: 2 days/week; progressive load, tempo control, multi-joint movements.

Stepwise approach:

• Start where the patient is; 10-minute walks 3x/week for sedentary individuals; gradually increase duration and frequency.
• Resistance training begins as one weekly session focusing on form; progress to two sessions with controlled overload.
• Celebrate all progress:

• Any increase from sedentary baseline yields significant health benefits; build confidence and sustainability.

Chiropractic integration:

• Reduce pain and correct biomechanics to prevent injuries; enable consistent exercise adherence; modulate autonomic tone to improve recovery.

References:

• Physical Activity Guidelines for Americans, 2nd edition (U.S. DHHS, 2018)

Sleep and Stress: Optimizing Recovery and Metabolism

Sleep architecture and metabolism:

• Poor sleep increases sympathetic output, cortisol, and inflammatory cytokines; worsens insulin resistance and appetite dysregulation.
• Sleep apnea:

• Treat with CPAP; improves nocturnal BP surges, insulin sensitivity, daytime function; supports exercise adherence.

Stress physiology:

• Chronic stress elevates cortisol; antagonizes insulin; impairs recovery and sleep; fuels cardiometabolic risk.

Interventions:

• Sleep hygiene:

• Consistent bed/wake times, dark, cool room, screen-free pre-sleep routine; CBT-I for insomnia.

• CPAP optimization:

• Mask fitting, humidification, nasal patency; chiropractic thoracic mobility for breathing comfort.

• Stress regulation:

• Mindfulness, breathwork, manualtherapy’ss parasympathetic effects; cognitive-behavioral tools.

References:

• Sleep duration and quality: impact on cardiometabolic health (St-Onge et al., 2017)
• OSA treatment and CV outcomes (Marin et al., 2012)

Liver Health: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Pathophysiology:

• Insulin resistance drives hepatic fat accumulation (steatosis) through de novo lipogenesis and FFA influx; inflammation and oxidative stress progress disease.

Weight loss thresholds:

• ~10% body weight reduction often required to reverse steatosis; greater losses improve fibrosis risk factors (Donnelly et al., 2005).

Interventions:

• Nutrition:

• Lower refined carbohydrates; fiber-rich whole foods; healthy fats; protein prioritization; reduce alcohol intake.

• Physical activity:

• Cardio and resistance training improve insulin sensitivity and hepatic lipid metabolism.

• Pharmacotherapy:

• GLP-1 RAs may reduce liver fat; coordinate with endocrinology/hepatology when advanced disease is suspected.

References:

• Fatty acid sources in NAFLD (Donnelly et al., 2005)

Dyslipidemia, ApoB, and Lp(a): Practical Clinical Steps

ApoB and risk:

• ApoB reflects particle count of atherogenic lipoproteins; superior to LDL-C alone for risk prediction; weight loss and statins reduce ApoB.

Lp(a) genetics:

• Elevated Lp(a) increases ASCVD risk; not modified by lifestyle; risk management intensifies LDL/ApoB lowering and broader CV prevention efforts.

Integrative plan:

• Weight loss (5%–15%).
• Mediterranean/DASH nutrition with soluble fiber.
• Exercise> 150 minutes/week.
• Statins as indicated; add obesity pharmacotherapy where eligible.

References:

• Guideline on blood cholesterol management (Grundy et al., 2019)

Hypertension De-Prescribing During Weight Loss: Safety and Monitoring

Rationale:

• Weight loss lowers BP; medications may require down-titration to prevent hypotension.

Protocol under Dr. Cardenas:

• Home BP monitoring and logs.
• Regular check-ins for symptoms (lightheadedness, fatigue).
• Adjust doses gradually; consider medication classes with favorable metabolic profiles.
• Choose obesity medications with neutral or BP-lowering effects (GLP-1 RAs).

References:

• 2017 ACC/AHA Guideline for High Blood Pressure (Whelton et al., 2018)

Pharmacotherapy in Obesity and Diabetes: GLP-1 and Dual-Agonist Therapies

Mechanisms:

• GLP-1 RAs:

• Enhance glucose-dependent insulin secretion, reduce glucagon, slow gastric emptying, reduce appetite; favor weight loss and improve glycemia; neutral or beneficial BP effects; potential hepatic fat reductions (Bray & Ryan, 2021).

• Dual GLP-1/GIP agonists (e.g., tirzepatide):

• Greater weight loss and A1c reductions in trials; appetite-suppressing synergy; titration reduces GI side effects.

Transitioning therapy:

• Move away from sulfonylureas to reduce hypoglycemia and weight gain.
• Reduce and discontinue insulin when GLP-1/dual agonists control glycemia; remove physiologic barrier to weight loss.

Safety:

• Gastrointestinal side effects common during titration; pause dose escalations when needed; monitor pancreatitis risk in select patients; coordinate with cardiology/hepatology as appropriate.

References:

• Update on drug treatment of obesity (Bray & Ryan, 2021)
• Tirzepatide versus semaglutide (Frias et al., 2021)
• Tirzepatide for obesity (Jastreboff et al., 2022)

Integrative Chiropractic Care: Biomechanics, Pain, Autonomic Regulation, and Functional Capacity

Clinical rationale:

• Pain reduces movement, undermining exercise prescriptions; biomechanics and soft tissue restrictions elevate energy cost of motion; autonomic dysregulation impairs recovery and sleep.
• Manual therapy and adjustments reduce nociception, restore joint kinematics, improve neuromuscular control, and optimize movement economy; autonomic down-regulation supports sleep, stress resilience, and glycemic stability.

Techniques:

• HVLA adjustments (when appropriate).
• Low-force mobilization for sensitized patients.
• Myofascial release and fascial glide.
• Neuromuscular activation and motor control retraining.
• Postural coaching and breathing mechanics, particularly thoracic cage dynamics relevant to sleep and activity.

Outcomes:

• Enable graded exercise plans; reduce flares; maintain adherence; support resistance training essential for sarcopenia prevention and muscle preservation.

Clinical observations:

• Patients adhere better when pain is controlled, and movement is coached in small increments.
• Sleep optimization magnifies metabolic benefits; CPAP adherence is a cornerstone; chiropractic rib and thoracic mobility improves breathing comfort.
• Combining manual therapy with resistance training and protein-forward nutrition accelerates body composition improvements.

References:

• Practice observations documented at Chiropracticscientist.com and LinkedIn profiles; integrated with exercise and obesity treatment evidence (Morton et al., 2018; Ivy, 1997; Phillips & Winett, 2010).

Team Communication and Patient Education: Setting Expectations and Milestones

Communication principles:

• Explain the “why” behind each intervention; connect physiology to protocols in plain language.
• Avoid vague promises; present realistic timelines and effort required.
• Co-create goals; proactively troubleshoot barriers; celebrate small wins.

Milestones:

• 5%: early metabolic changes in prediabetes and diabetes.
• 5%: improvements in dyslipidemia, mobility, mood, quality of life.
• 10%: significant BP and MASLD changes; event risk reductions.
• 15%+: deeper cardiometabolic remodeling; potential disease remission in select cases.

Tracking:

• Waist circumference, BP logs, A1c and fasting glucose at intervals, triglycerides and ApoB trends, sleep reports, and functional tests (grip strength, chair stands).
• DEXA or BIA for composition updates; CAC scoring as indicated.

References:

• Weight Loss and Comorbidity Improvements (Ryan & Yockey, 2017)

Bringing It All Together: From Risk to Resilience

At Injury Medical Clinic PA in El Paso, we are committed to modern, evidence-based, integrative care. With Dr. C. Cardenas’s medical direction and my chiropractic and functional medicine integration, we help patients move from pain to performance, from risk to resilience, and from knowledge to action.

We deploy personalized, multi-domain plans:

• Reduce adiposity while preserving or increasing lean mass.
• Aggressively manage hypertension, dyslipidemia, insulin resistance, and sleep apnea.
• Treat sarcopenic obesity with resistance training, protein prioritization, and safe progression under rehab.
• Use GLP-1/dual-agonist pharmacotherapy judiciously to unlock weight loss and cardiometabolic benefits.
• Integrate chiropractic methods to facilitate movement, reduce pain, and modulate autonomic function.
• Monitor outcomes and de-prescribe medications safely during weight loss.
• Advocate for patients against bias, ensuring access to comprehensive care (e.g., orthopedic evaluations for severe OA).

Our integrated model is designed to be clear, actionable, and effective—anchored in physiology and modern clinical trials, and powered by multidisciplinary collaboration.

References

• Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease (Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J., 2005). Journal of Clinical Investigation, 115(5), 1343–1351.
• Weight Loss and Improvement in Comorbidities: Differences at 5%, 10%, 15%, and Over (Ryan, D. H., & Yockey, S. R., 2017). Current Obesity Reports, 6(2), 187–194.
• Obesity: Epidemiology, Pathophysiology, and Therapeutics (Lin, X., & Li, H., 2021). Frontiers in Endocrinology, 12, 706978.
• The role of the primary care provider in the prevention and treatment of obesity (Aronne, L. J., Horn, D. B., & Kahan, S., 2018). The Journal of Family Practice, 67(3 Suppl), S3–S8.
• Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation (Lingvay, I., Sumithran, P., & Cohen, R. V., 2022). The Lancet, 399(10322), 394–405.
• Medical Management of Obesity (Ryan, D. H., Lingvay, I., & El-Toukhy, T., 2022). In Feingold et al. (Eds.), Endotext. MDText.com, Inc.
• Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association (Powell-Wiley, T. M., Poirier, P., & Burke, L. E., 2021). Circulation, 143(21), e984–e1010.
• 2018 AHA/ACC Guideline on the Management of Blood Cholesterol (Grundy, S. M., Stone, N. J., & Bailey, A. L., 2019). Circulation, 139(25), e1082–e1143.
• 2017 ACC/AHA Guideline for High Blood Pressure in Adults (Whelton, P. K., Carey, R. M., & Aronow, W. S., 2018). Journal of the American College of Cardiology, 71(19), e127–e248.
• AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity (Garvey, W. T., Mechanick, J. I., & Brett, E. M., 2016). Endocrine Practice, 22(Suppl 3), 1–203.
• The “skinny” on visceral fat and its link to cardiovascular disease (Lin, X., & Li, H., 2021). Frontiers in Cardiovascular Medicine, 8, 706978.
• The “4Ms” of obesity: A new framework for determining the medically necessary treatment of obesity (Ryan, D. H., & Heaner, M. K., 2014). Obesity, 22(10), 2153–2155.
• AMA’s Resolution on Obesity as a Disease: A Call to Action for a New Standard of Care (Mechanick, J. I., & Kushner, R. F., 2016). JAMA, 315(21), 2281–2282.
• Epicardial fat in HFpEF (Borlaug, B. A., & Jensen, M. D., 2013). Journal of the American College of Cardiology, 61(8), 838–840.
• Guideline-recommended obesity treatment tools: a review of the evidence (Ryan, D. H., & Kahan, S., 2018). Current Medical Research and Opinion, 34(2), 193–200.
• Update on drug treatment of obesity (Bray, G. A., & Ryan, D. H., 2021). Annals of the New York Academy of Sciences, 1495(1), 3–15.
• Ultra-processed diets cause excess calorie intake and weight gain (Hall, K. D., et al., 2019). Cell Metabolism, 30(1), 67–77.e3.
• The carbohydrate-insulin model of obesity (Ludwig, D. S., & Ebbeling, C. B., 2018). JAMA Internal Medicine, 178(8), 1098–1103.
• Tirzepatide once weekly for the treatment of obesity (Jastreboff et al., 2022). New England Journal of Medicine, 387(3), 205–216.
• Tirzepatide versus semaglutide in T2D (Frias, J. P., et al., 2021). New England Journal of Medicine, 385(6), 503–515.
• 10-year follow-up of intensive glucose control in T2D (Holman, R. R., et al., 2008). New England Journal of Medicine, 359(15), 1577–1589.
• CPAP treatment of OSA and metabolic syndrome (Gottlieb, D. J., et al., 2010). American Journal of Respiratory and Critical Care Medicine, 181(9), 964–971.
• OSA-hypopnea: long-term cardiovascular outcomes (Marin, J. M., et al., 2012). The Lancet, 379(9832), 1831–1838.
• Exercise training and insulin resistance (Ivy, J. L., 1997). Sports Medicine, 23(5), 347–364.
• Resistance training: adiposity and metabolic markers (Phillips, S. M., & Winett, R. A., 2010). Obesity, 18(1), 45–50.
• Incidence of erectile dysfunction and diabetes risk factors (Johannes, C. B., et al., 2000). Journal of Urology, 163(2), 460–463.
• The emergence of the metabolic syndrome with menopause (Carr, M. C., 2003). Journal of Clinical Endocrinology & Metabolism, 88(6), 2404–2411.
• Longitudinal changes in body composition across menopause (Toth, M. J., et al., 2000). Journal of Clinical Endocrinology & Metabolism, 85(4), 1658–1662.
• Estrogen and bone turnover in postmenopausal women (Khosla, S. et al., 1997). Journal of Clinical Investigation, 99(9), 1903–1907.
• Estrogen/testosterone effects on bone in men (Finkelstein, J. S., et al., 2008). New England Journal of Medicine, 359(16), 1805–1816.
• Protein intake to maximize muscle mass and strength (Morton, R. W., et al., 2018). British Journal of Sports Medicine, 52(6), 376–384.
• Myofibrillar muscle protein synthesis: leucine, dose, and age (Witard, O. C., et al., 2016). American Journal of Clinical Nutrition, 103(3), 708–716.
• Duration of vasomotor symptoms of menopause (Avis, N. E., et al., 2014). JAMA Internal Medicine, 175(4), 531–539.
• Abdominal adiposity and hot flashes among midlife women (Thurston, R. C., et al., 2011). Obesity, 19(5), 1069–1074.
• Menopause management and chronic disease prevention (Manson, J. E., et al., 2016). JAMA, 316(16), 1695–1696.
• Sleep duration and quality: impact on lifestyle behaviors (St-Onge, M. P., et al., 2017). Circulation, 135(15), e875–e889.
• Physical Activity Guidelines for Americans, 2nd edition (U.S. Department of Health and Human Services, 2018).
• GLIM criteria for malnutrition diagnosis (Cederholm, T. et al., 2019). Clinical Nutrition, 38(1), 1–9.
• Sarcopenia: revised European consensus (EWGSOP2) (Cruz-Jentoft, A. J., et al., 2019). Age and Aging, 48(1), 16–31.
• Sarcopenic obesity: clinical implications (Donini, L. M., et al., 2016). Journal of Cachexia, Sarcopenia and Muscle, 7(5), 497–505.

SEO tags: Obesity Treatment, Cardiometabolic Health, Integrative Chiropractic Care, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso TX, Functional Medicine, Insulin Resistance, Heart Failure, HFpEF, SELECT Trial, Semaglutide, Tirzepatide, Hypertension Management, Dyslipidemia, Visceral Fat, Weight Loss Benefits, Midlife Health, Menopause, Adiposity, Body Composition, Cardiovascular Risk Reduction, Multidisciplinary Clinic, Personal Injury Care, Rehabilitation, Sarcopenic Obesity, CPAP Adherence, Protein Prioritization, Resistance Training, DASH Diet, Mediterranean Diet, ApoB, Lipoprotein(a), MASLD, Sleep Optimization, Autonomic Regulation, Chiropractic Thoracic Mobility, Clinical Observations, Chiropracticscientist.com, LinkedIn Dr. Alex Jimenez